Molina Healthcare vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Long Beach CA Medicaid managed care (NYSE: MOH) ~$38.7B FY2024 revenue; 5.7M members in 19 states, Medicaid redetermination management, D-SNP growth competing with Centene and Elevance.
About
Molina Healthcare, Inc. is a Long Beach, California-based managed care organization — publicly traded on the New York Stock Exchange (NYSE: MOH) as an S&P 500 Health Care component — providing Medicaid, Medicare, and Marketplace (Affordable Care Act exchange) health insurance through state-contracted managed care plans to approximately 5.7 million low-income, elderly, and disabled members across 19 states, with revenues generated primarily from per-member-per-month (PMPM) capitation payments received from state Medicaid agencies and CMS Medicare programs. In fiscal year 2024, Molina Healthcare reported revenues of approximately $38.7 billion — primarily from Medicaid capitation payments from state Medicaid agencies that contract with Molina to administer benefits for enrolled beneficiaries — generating net income impacted by elevated medical costs in the Marketplace segment as post-COVID health utilization normalization drove medical loss ratios above expectations. CEO Joseph Zubretsky's strategy of disciplined Medicaid contract renewal and Medicaid redetermination management positioned Molina for the 2023-2024 Medicaid unwinding — the federal pandemic-era continuous enrollment requirement expiration required states to redetermine eligibility for all Medicaid enrollees, with Molina proactively assisting ineligible members transition to Marketplace plans to retain the relationship. Molina's marketplace business expansion (Affordable Care Act exchange plans in new states and existing markets) provides enrollment growth offsetting Medicaid membership losses from redetermination, while Medicare Dual Eligible Special Needs Plans (D-SNPs — serving members eligible for both Medicaid and Medicare) represent the highest-growth and highest-margin Molina product line.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Also Compare
Molina Healthcare vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.